About Forma Therapeutics
Forma Therapeutics is a company based in Watertown (United States) founded in 2007 was acquired by Novo Nordisk in September 2022. Forma Therapeutics has raised $417.55 million across 8 funding rounds from investors including Novartis, Novo Nordisk and Janus Henderson Investors. The company has 165 employees as of December 31, 2021. Forma Therapeutics offers products and services including Ozempic. Forma Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Denali Therapeutics, C4 Therapeutics, Erasca and Revolution Medicines, among others.
- Headquarter Watertown, United States
- Employees 165 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Novo Nordisk A/S
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$417.55 M (USD)
in 8 rounds
-
Latest Funding Round
$100 M (USD), Series D
Dec 19, 2019
-
Investors
Novartis
& 10 more
-
Employee Count
165
as on Dec 31, 2021
-
Acquired by
Novo Nordisk
(Sep 01, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Forma Therapeutics
Forma Therapeutics offers a comprehensive portfolio of products and services, including Ozempic.
Medication for managing type 2 diabetes and improving patient outcomes.
People of Forma Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Forma Therapeutics
Forma Therapeutics has successfully raised a total of $417.55M across 8 strategic funding rounds. The most recent funding activity was a Series D round of $100 million completed in December 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Forma Therapeutics
Forma Therapeutics has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Novartis, Novo Nordisk and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital funding is provided by Samsara BioCapital in California.
|
Locked | Locked | Locked | |
|
Multiple sectors are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Early-stage life sciences investments are targeted in the healthcare sector.
|
Locked | Locked | Locked |
Investor details for Forma Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Forma Therapeutics
Investment portfolio details for Forma Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Forma Therapeutics
Detailed financials for Forma Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Forma Therapeutics Comparisons
Peer comparison for Forma Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Forma Therapeutics
Forma Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Denali Therapeutics, C4 Therapeutics, Erasca and Revolution Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
Detailed competitors of Forma Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Forma Therapeutics
Complete news archive for Forma Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Forma Therapeutics
Forma Therapeutics was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Forma Therapeutics is headquartered in Watertown, United States.
Frank Lee is the current CEO of Forma Therapeutics.
Forma Therapeutics is a funded company, having raised a total of $417.55M across 8 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Forma Therapeutics is 165.
Forma Therapeutics was founded in 2007 and is based in Watertown, United States. Operations focus on biotechnology, where drug discovery engines are utilized to screen and apply structure-based methods across targets in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. Lead candidates such as FT-4202 for sickle cell disease, FT-7051 for acute myeloid leukemia, and olutasidenib for glioma are advanced through development pipelines.
Forma Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Forma Therapeutics offers Ozempic.
Forma Therapeutics has 11 investors. Key investors include Novartis, Novo Nordisk, Janus Henderson Investors, RA Capital, and Celgene.